Investment Rating - The report indicates a positive outlook for the cosmetics and medical beauty sector, with strong performance compared to the market [2][3]. Core Insights - Estee Lauder reported double-digit growth in China, with net sales reaching RMB 29.35 billion, a year-on-year increase of 6%, and profits improving by 127% to RMB 1.12 billion [8][26]. - The Tmall beauty category saw a significant increase of 24% year-on-year in January 2026, indicating strong consumer demand and confidence in the market [8][29]. - The report highlights the government's focus on promoting service consumption, which is expected to drive growth in key sectors, including beauty and personal care [9][10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector outperformed the market, with the Shenwan Beauty Care Index rising by 3.7% from January 30 to February 6, 2026 [3]. - The Shenwan Cosmetics Index increased by 2.8%, outperforming the Shenwan A Index by 4.4 percentage points [3]. Company Highlights - Estee Lauder's sales in mainland China surged by 13% to RMB 6.44 billion, confirming the recovery of international beauty brands in the Chinese market [8][26]. - The report notes that the top-performing stocks in the sector included Betaini (+13.5%), Huaxi Biological (+12.0%), and Beijia Clean (+10.8%) [4]. E-commerce Insights - The report provides data on the performance of domestic brands on platforms like Douyin and Tmall, showing significant growth in GMV for several brands [20]. - For instance, the brand "毛戈平" saw a GMV increase of 298% in December 2025 [21]. Market Trends - The overall retail sales of cosmetics in December 2025 grew by 8.8%, with a total retail sales figure of RMB 465.3 billion for the year, reflecting a steady recovery in consumer spending [22][23]. - The report emphasizes the shift in consumer preferences towards personalized and high-quality products, indicating a strategic opportunity for brands to innovate [10][11].

穆迪：将艾伯维评级上调至A2，展望稳定。 来源：滚动播报 ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies’ results and how they’re being received by investors. Today, we’re offering insight into the latest numbers from Bristol Myers Squibb, GSK and AbbVie. AbbVie angst AbbVie reported $16.6 billion worth of net revenue in the final three months of 2025, a 10% year-over-yea ...

Market Overview - Stock futures are mixed, showing signs of stabilization after a downturn in software and AI-related technology stocks, leading some investors to view the selloff as a buying opportunity [1] - Defensive sectors and commodity-linked assets are gaining interest, particularly as gold prices have risen above $5,000 per ounce, indicating strong demand for safe havens amid market uncertainty [1] Pre-Market Trading - In pre-market trading, S&P 500 futures rose by 0.11%, Nasdaq futures fell by 0.34%, and Dow futures increased by 0.22% [2] Company Movements - Silicon Labs (SLAB) shares surged by 49% following a definitive agreement for acquisition by Texas Instruments (TXN) at $231 per share in an all-cash transaction [3] - Texas Instruments (TXN) shares declined by 3% after announcing the acquisition of Silicon Labs [6] - Other notable stock movements include Eli Lilly (LLY) up 9%, Johnson Controls (JCI) up 5%, and AMD (AMD) down 10% [6]

It has been quite a while since I've covered AbbVie Inc. ( ABBV ). Back in August of last year, I initiated coverage with a buy rating as earnings were strong and their RinvoqI'm a full-time investor with a strong focus on the tech sector. I graduated with a Bachelor of Commerce Degree with Distinction, major in Finance. I'm also a proud lifetime member of the Beta Gamma Sigma International Business Honor Society. My core values are: Excellence, Integrity, Transparency, & Respect. I always, to the best of m ...

Core Insights - AbbVie Inc. (ABBV) was previously covered with a buy rating due to strong earnings and the performance of their drug Rinvoq [1] Company Overview - AbbVie Inc. is a pharmaceutical company that has shown strong earnings performance, which has positively influenced its stock rating [1] Analyst's Perspective - The analysis emphasizes the importance of constructive feedback to enhance the quality of investment insights [1]

It has been two years since I last covered AbbVie ( ABBV ) on Seeking Alpha. At that time, the stock had been stuck in a $130 to $170 range since 2022 on worries aboutI retired early after 22 years in the energy industry with roles in engineering, planning, and financial analysis. I have managed my own portfolio since 1998 and have met my goal to match the S+P 500 return over the long term with lower volatility and higher income. I mostly write on positions I already hold or am considering changing. I prefe ...

Core Insights - AbbVie (ABBV) stock has been trading in a range of $130 to $170 since 2022, primarily due to concerns regarding its future performance [1]. Group 1 - The author has not covered AbbVie for two years, indicating a significant period of observation without updates [1]. - The author has a long-term investment strategy, focusing on maximizing total return by purchasing stocks when they are undervalued relative to their intrinsic value [1]. Group 2 - The author holds a beneficial long position in AbbVie shares, indicating confidence in the company's future performance [2]. - The article reflects the author's personal opinions and is not influenced by any external compensation or business relationships [2].

Core Viewpoint - AbbVie Inc. is a leading biopharmaceutical company with strong financial performance in Q4 2025, driven by its immunology portfolio, and is projected to exceed profit expectations for 2026 [1][2][6] Financial Performance - AbbVie reported Q4 2025 sales of $16.62 billion, exceeding the consensus estimate of $16.42 billion, marking a 10% increase on a reported basis and a 9.5% increase operationally [2] - Adjusted earnings per share rose by 25.5% to $2.71, surpassing the expected $2.65 [2] Revenue Breakdown - The immunology portfolio generated global net revenues of $8.63 billion, reflecting an 18.3% increase, with Skyrizi sales up 32.5% to $5.01 billion and Rinvoq sales rising 29.5% to $2.37 billion [3] - Neuroscience sales climbed to $2.96 billion, a 17.9% increase, with Vraylar contributing $1.02 billion (up 10.5%) and Botox Therapeutics at $991 million (up 13.4%) [4] - The oncology portfolio saw a slight decline, generating $1.66 billion in sales, with Imbruvica's revenues down 20.8% to $671 million, while Venclexta's revenues increased by 8.6% to $711 million [4] Future Projections - AbbVie projects its 2026 profit to surpass Wall Street estimates, driven by strong sales of Skyrizi and Rinvoq [5][6] - The current stock price of ABBV is $216.97, reflecting a decrease of 3.85% or $8.69, with a market capitalization of approximately $383.47 billion [5]

Core Insights - The article highlights the offerings of Biotech Analysis Central, a service focused on deep-dive analysis of pharmaceutical companies, providing valuable insights for investors in the biotech sector [1][2]. Group 1: Company Overview - Biotech Analysis Central is led by Terry Chrisomalis, who has extensive experience in the biotech sector and aims to generate long-term value from healthcare investments [2]. - The service includes a library of over 600 biotech investing articles and a model portfolio featuring more than 10 small and mid-cap stocks, each with in-depth analysis [2]. Group 2: Subscription Details - The subscription to Biotech Analysis Central is priced at $49 per month, with a promotional offer of a 33.50% discount for annual subscriptions, bringing the yearly cost to $399 [1].